Table 2.
Pathological characteristics of PMN patients with SAb + and without associated diseases or diabetes.
| PMN | All Patients | P value | ||
|---|---|---|---|---|
| n (%) | (n = 474) | eGFR≧60 mL/min/1.73 m2(n = 436) | eGFR < 60 mL/min/1.73 m2(n = 38) | |
| Stage I | 8(1.7) | 6(1.4) | 2(5.3) | 0.020 |
| Stage II | 278(58.6) | 270(61.9) | 8(21.1) | |
| Stage III | 175(36.9) | 150(34.4) | 25(65.8) | |
| Stage IV | 13(2.7) | 10(2.3) | 3(7.9) | |
| Additional biopsy findings, n (%) | 102(21.5) | 71(16.3) | 31(81.6) | 0.000 |
| IgAN | 17(3.9) | 0(0) | 0.383 | |
| ORG | 23(5.3) | 2(5.3) | 1.000 | |
| ATI | 7(1.6) | 11(28.9) | 0.000 | |
| ATIN/SATIN | 6(1.4) | 6(15.8) | 0.000 | |
| IRI | 7(1.6) | 5(13.2) | 0.000 | |
| Others | IgAN with IRI(n = 1) IgA deposition(n = 6) Endothelial cell injury(n = 2) TMA(n = 2) | ATI with IRI(n = 3) SATIN with IRI(n = 1) IgA deposition(n = 1) Crescents(n = 2) | ||
ORG obesity-related glomerulopathy, ATI acute tubular injury, IRI ischemic renal injury, ATIN/SATIN acute tubulointerstitial nephropathy/subacute tubulointerstitial nephropathy, TMA thrombotic microangiopathy.